Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) AI Stock Analysis

• Market Cap: HK$308.75M
• Dividend Yield: 2.92%
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): 11.4
• Beta (1Y): 0.18
• Revenue Growth: -4.17%
• EPS Growth: -1.83%
• Country: HK
• Employees: 1,485
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.02
• Shares Outstanding: 426,000,000
• 10 Day Avg. Volume: 586,000
• 30 Day Avg. Volume: 1,496,333
• PEG Ratio: 0.09
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ―

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. holds a solid financial foundation with a strong balance sheet, but it faces significant operational challenges, including declining revenues and zero cash flow. Despite strong technical indicators, the stock's overvaluation limits its attractiveness. Investors should be cautious due to potential liquidity issues and market volatility risks.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.

How the Company Makes Money

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. generates revenue primarily through the sale of its biopharmaceutical products. The company's key revenue streams include the production and distribution of vaccines, which are sold to healthcare providers and government agencies, and therapeutic biological products, which are sold to hospitals and medical institutions. Additionally, the company may engage in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and expand its market reach. Revenue is also generated from diagnostic reagents used in medical testing and research, contributing to the company’s overall financial performance.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Financial Statement Overview

Summary

The company shows strong balance sheet metrics with a high equity ratio and low debt-to-equity ratio, indicating financial stability. However, declining revenues, margins, and concerning cash flow metrics reflect operational challenges and liquidity risks.

Income Statement

The company experienced a decline in revenue from 2023 to 2024, indicating a potential challenge in maintaining sales momentum. Gross profit margin decreased from 41.3% in 2023 to 31.5% in 2024, suggesting increased cost pressures or pricing challenges. Net profit margin slightly improved to 2.4% in 2024 from 2.3% in 2023, reflecting some operational efficiencies. EBIT and EBITDA margins also show a decline, emphasizing operational headwinds.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 66.7% in 2024, indicating good financial stability. The debt-to-equity ratio remains low at 0.11, suggesting conservative leverage practices. However, slight declines in total assets and stockholders' equity could pose future challenges if not addressed.

Cash Flow

Cash flow metrics are concerning, with operating cash flow dropping to zero in 2024, potentially impacting liquidity. With free cash flow also at zero, the company may face challenges in funding new investments or expansions without additional financing.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.04B	1.06B	986.69M	838.80M	1.03B
	Gross Profit
328.04M	439.24M	444.14M	374.10M	574.36M
	EBIT
34.72M	36.25M	89.29M	43.71M	51.04M
	EBITDA
62.87M	69.89M	125.24M	73.97M	76.74M
	Net Income Common Stockholders
25.01M	24.13M	54.35M	35.96M	36.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
283.42M	382.21M	350.10M	311.14M	415.88M
	Total Assets
1.40B	1.42B	1.45B	1.31B	1.12B
	Total Debt
105.43M	89.69M	92.69M	105.69M	10.06M
	Net Debt
-177.99M	-282.52M	-197.41M	-121.45M	-401.83M
	Total Liabilities
371.99M	399.46M	442.93M	363.17M	225.21M
	Stockholders Equity
933.18M	908.17M	884.04M	829.70M	793.74M
Cash Flow		Free Cash Flow
0.00	38.32M	41.51M	-85.00M	55.69M
	Operating Cash Flow
0.00	53.69M	61.22M	-69.92M	93.64M
	Investing Cash Flow
0.00	60.90M	10.76M	-181.57M	-30.68M
	Financing Cash Flow
0.00	-32.48M	-9.02M	66.75M	-35.28M

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8329, the sentiment is Positive. The current price of 0.18 is below the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.17, and above the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.36 is Neutral, neither overbought nor oversold. The STOCH value of 25.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8329.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8329	58 Neutral	HK$308.75M	11.36	2.72%	2.92%	-4.17%	-1.83%
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
PIAIF		$126.40B	6.15		7.53%	―	―
SBMFF		$11.37B	46.87	6.14%	1.60%	―	―
CHJTF		$11.16B	20.51	13.20%	2.46%	―	―
LVZPF		$4.11B	11.49	14.56%	0.58%	―	―
TRSBF		$6.36B	24.62	14.19%	1.17%	―	―